TY - JOUR T1 - Estimating the state of the Covid-19 epidemic in France using a non-Markovian model JF - medRxiv DO - 10.1101/2020.06.27.20141671 SP - 2020.06.27.20141671 AU - Raphaël Forien AU - Guodong Pang AU - Étienne Pardoux Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/29/2020.06.27.20141671.abstract N2 - In this paper, we use a deterministic non-Markovian epidemic model to estimate the state of the Covid-19 epidemic in France. This model allows us to consider realistic distributions for the exposed and infectious periods in a SEIR model, contrary to standard ODE models which only consider exponentially distributed exposed and infectious periods. We present theoretical results linking the (unobserved) parameters of the model to various quantities which are more easily measured during the early stages of an epidemic. We also stress the main quantitative differences between the non-Markovian and the Markovian (ODE) model. We then apply these results to estimate the state of the Covid-19 epidemic in France by analyzing three regions: the Paris region, the northeast regions and the rest of the country, based on current knowledge on the infection fatality ratio and the exposed and infectious periods distributions for Covid-19. Our analysis is based on the hospital data published daily by Santé Publique France (daily hospital admissions, intensive care unit admissions and hospital deaths).Competing Interest StatementThe authors have declared no competing interest.Funding StatementNAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:NAAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data used in this article is made public by Santé Publique France and is freely available online. https://www.data.gouv.fr/fr/datasets/donnees-hospitalieres-relatives-a-lepidemie-de-covid-19/ ER -